RT Journal Article
SR 00
ID 10.1002/ehf2.13476
A1 Raafs, Anne
A1 Verdonschot, Job
A1 Ferreira, Joao Pedro
A1 Wang, Ping
A1 Collier, Timothy
A1 Henkens, Michiel
A1 Björkman, Jens
A1 Boccanelli, Alessandro
A1 Clark, Andrew L.
A1 Delles, Christian
A1 Diez, Javier
A1 González, Arantxa
A1 Girerd, Nicolas
A1 Jukema, J. Wouter
A1 Pinet, Florence
A1 Rossignol, Patrick
A1 Thum, Thomas
A1 Vodovar, Nicolas
A1 de Boer, Rudolf A.
A1 van Empel, Vanessa
A1 Staessen, Jan A.
A1 Hazebroek, Mark
A1 Cleland, John
A1 Zannad, Faiez
A1 Heymans, Stephane
T1 Identification of sex‐specific biomarkers predicting new‐onset heart failure
JF ESC Heart Failure
YR 2021
FD 2021-10
VO 8
IS 5
SP 3512
OP 3520
AB Aims:  Heart failure (HF) is common in both men and women, yet disease pathophysiology, presentation, and progression differ between sexes. Studies addressing whether biomarkers predict new onset HF sex-specifically are scarce. This study therefore aims to test the sex-specificity of 252 protein biomarkers for new-onset HF.    Methods and results:  A matched case–control design in patients selected from cohorts within the HOMAGE consortium was used. Cases (new-onset HF, n = 562) and controls (n = 780) were matched for cohort (PREDICTOR, HEALTH-ABC, & PROSPER), follow-up time (defined as time from entry to incident HF), and age. Incident HF was defined as first hospitalization for HF. Targeted plasma proteins (n = 252) were measured using Proximity Extension Assay technology from O-link. To look for sex differences for new onset HF, we adjusted for cohort, age, and baseline clinical parameters. At baseline, women had a biomarker profile reflecting activated metabolism and immune responses. However, none of the biomarkers had a significant interaction with sex in predicting new onset HF, but four biomarkers had a trend towards sex-specificity (P < 0.013). E-selectin and interleukin 1 receptor antagonist were more female-specific, whereas IL17A and CHIT1 tended to be male sex-specific for incident HF.    Conclusions:  The majority of biomarkers associated with incident HF did not significantly differ between women and men, despite clear differences in biomarkers at baseline.
NO The research leading to these results has received funding from the European Union Commission's Seventh Framework Programme under grant agreement 305507 [HOMAGE (Heart Omics in Ageing consortium)]. We acknowledge the support from the Netherlands Cardiovascular Research Initiative, an initiative with the support of the Dutch Heart Foundation CVON2016-Early HFPEF, and CVON 2017-21, SHE-PREDICTS-HF. JPF, NG, PR, and FZ are supported by the Contrat de Plan Etat-Lorraine and FEDER Lorraine, and a public grant overseen by the French National Research Agency (ANR) as part of the second “Investissements d'Avenir” programme FIGHT-HF (reference: ANR-15-RHU-0004) and by the French PIA project “Lorraine Université d'Excellence”, reference ANR-15-IDEX-04-LUE. They thank the CRB lorrain for biobaking activities. JAS is supported by the Non-Profit Research Institute Alliance for the Promotion of Preventive Medicine (URL: http://www.appremed.org), Mechelen, Belgium received a non-binding research grant from OMRON Healthcare Co., Ltd., Kyoto, Japan.
PB Wiley
SN 2055-5822
LK https://eprints.gla.ac.uk/244600/